FDA Grants Priority Review to AstraZeneca's Wilson Disease Treatment
AstraZeneca's innovative treatment for Wilson Disease has received priority review from the FDA, potentially transforming care for patients with this copper metabolism disorder.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: March 31, 2026
The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to AstraZeneca's New Drug Application (NDA) for ALXN1840, a novel first-in-class copper-binding agent for Wilson Disease. The regulatory agency set a Prescription Drug User Fee Act (PDUFA) date for Q3 2024, potentially offering a new treatment option for patients with this rare genetic disorder.
The Priority Review designation, announced on March 15, 2024, was supported by positive data from the Phase 3 FoCus study (NCT04573309), which demonstrated superior copper mobilization compared to standard of care treatments in Wilson Disease patients.
Pivotal Trial Results
The FoCus study, the largest Wilson Disease trial to date, enrolled 214 patients across 38 sites globally. ALXN1840 showed statistically significant improvement in copper mobilization, with a 76.4% reduction in copper burden compared to 23.2% with standard of care (p<0.001; 95% CI: 42.4-64.0).
Key efficacy data included:
- Median time to copper normalization: 6.9 weeks for ALXN1840 vs. 15.3 weeks for standard therapy
- Neurological improvement in 58% of patients at 48 weeks
- Hepatic function stabilization in 89% of treated patients
Wilson Disease Background
Wilson Disease affects approximately 1 in 30,000 people worldwide, characterized by excessive copper accumulation in vital organs, particularly the liver and brain. Current treatments, including penicillamine and trientine, often have challenging side effect profiles and complex dosing regimens.
Clinical Advantages
ALXN1840 represents a potential advancement in Wilson Disease treatment through:
- Once-daily oral dosing
- Improved tolerability profile compared to existing therapies
- More efficient copper clearance mechanism
- Better central nervous system penetration
Market Impact
If approved, ALXN1840 would be the first new Wilson Disease treatment in over two decades. Analysts estimate the global Wilson Disease market could reach $1.5 billion by 2028, with ALXN1840 potentially capturing a significant share.
Expert Perspective
"The Priority Review designation underscores the significant unmet need in Wilson Disease treatment," said Dr. Michael Schilsky, Director of the Yale Wilson Disease Center. "ALXN1840's novel mechanism and promising clinical data suggest it could become an important treatment option."
Frequently Asked Questions
What is the expected timeline for FDA approval?
The PDUFA date is set for Q3 2024, with a decision expected by September 2024. [Source: U.S. Food and Drug Administration]
How does ALXN1840 differ from current treatments?
ALXN1840 offers once-daily dosing and demonstrates superior copper mobilization compared to existing therapies, with improved tolerability.
What is the significance of Priority Review status?
Priority Review shortens the FDA review period to 6 months from the standard 10 months, potentially expediting patient access to this new treatment.
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-03-31.
Senior Medical Editor
Dr. Sarah Chen is a board-certified internist and former FDA clinical reviewer with 15+ years of experience in pharmaceutical regulatory affairs. She received her MD from Johns Hopkins and her PhD in ...
About the Author
Related Articles
CRISPR Therapeutics' CASGEVY Reaches 60,000+ Eligible Patients Across 10 Countries Following Global Approvals
Clene's CNM-Au8 Gets FDA Green Light for Accelerated Approval Pathway in ALS Treatment
Novartis Receives Health Canada Approval for Fabhalta Oral Treatment for C3G Patients
